S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
QURE · uniQure N.V. Ordinary Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$22.68
-0.02
(-0.07%)
● At close: October 21 at 4:00:00 PM EDT
$23.00
+0.31
(+1.37%)
Overnight:
10:24:29 PM EDT
DAY'S RANGE
$22.68
$22.34
$23.05
52-WEEK RANGE
$22.68
$8.73
$71.50
What's happening
- QURE is down 0.07% today, trading at $22.68. — Live quote
- Volume today (43,815) is well below its 3-month average of 2,217,930. (Finnhub fundamentals)
- Reports earnings on 2026-11-10 (before market open), 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.22 actual vs. $-0.84 estimated (-45.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 9
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
QURE
-5.08%
vs S&P 500
-17.85%
1-YEAR RETURN
QURE
-64.46%
vs S&P 500
-79.02%
6-MONTH RETURN
QURE
+35.13%
3-MONTH RETURN
QURE
-43.34%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.22
Est. $-0.84
MISS -45.1%
2026-04-26 (Q1 2026)
$-0.85
Est. $-0.89
BEAT +4.9%
2026-01-26 (Q4 2025)
$-0.64
Est. $-0.97
BEAT +33.7%
2025-10-26 (Q3 2025)
$-1.38
Est. $-0.92
MISS -50.4%
Valuation Measures & Ratios
Enterprise Value4$1.70B
Forward P/E5—
PEG Ratio6-1.73
Price / Sales (TTM1)84.39
Price / Book79.66
EV4 / Revenue91.16
EV4 / EBITDA5.52
Profit Margin-1350.73%
Operating Margin-1071.53%
Return on Equity (ROE8)-111.96%
Return on Assets (ROA9)-29.01%
Avg Volume (3M)2,217,930
Quarterly history (5 periods)
| Measure | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 |
|---|---|---|---|---|---|
| Market cap | $1.03B | $113.8M | $25.7M | $18.6M | — |
| P/E | -4.78 | -0.55 | -0.14 | — | — |
| Price/Book | 6.89 | 0.50 | -6.42 | 0.55 | — |
| ROE | -144.25% | -90.17% | 4547.41% | — | — |
| ROA | -27.66% | -23.22% | -31.12% | — | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short8,715,837
Change from Prior Settlement-12.14%
% of Float—
Days to Cover (Short Ratio)1.94
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 11.0% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -1350.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -64.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on QURE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M | — | — | $1.6M | — | — | — | — |
| Operating income | -$45.7M | -$51.0M | -$43.9M | -$39.3M | -$40.2M | -$44.0M | -$54.2M | -$81.9M |
| Net income | -$53.5M | -$80.5M | -$37.7M | -$43.6M | -$44.4M | -$56.3M | — | — |
| EPS (diluted) | $-0.85 | $-1.38 | $-0.69 | $-0.82 | $-0.91 | $-1.16 | $-1.36 | $-1.88 |
| EPS (basic) | $-0.85 | $-1.38 | $-0.69 | $-0.82 | $-0.91 | $-1.16 | $-1.36 | $-1.88 |
| Operating margin | -$1.3K | — | — | -$2.5K | — | — | — | — |
| Net margin | -$1.5K | — | — | -$2.8K | — | — | — | — |
Balance sheet
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $778.7M | $824.9M | $888.4M | $584.9M | $605.4M | $556.5M | $645.8M | $730.8M |
| Total liabilities | $629.4M | $626.0M | $659.6M | $588.9M | $571.7M | $563.3M | $590.0M | $633.7M |
| Stockholders' equity | $149.3M | $198.9M | $228.7M | -$4.0M | $33.7M | -$6.8M | $55.8M | $97.1M |
| Total current assets | $615.7M | $656.0M | $716.2M | $408.6M | $435.4M | $390.3M | $464.1M | $592.0M |
| Total current liabilities | $59.2M | $62.9M | $100.6M | $40.9M | $36.3M | $40.1M | $71.3M | $80.5M |
| Cash & equivalents | $140.0M | $80.2M | $597.1M | $253.8M | $217.2M | $158.9M | $251.6M | $287.9M |
| Accounts receivable | $3.6M | $5.9M | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $12.0M | $13.8M | $15.4M | $17.5M | $18.1M | $20.4M | $25.6M | $26.2M |
| Goodwill | $24.8M | $25.4M | $25.3M | $25.3M | $23.4M | $22.4M | $24.1M | $23.1M |
| Intangible assets | $70.0M | $72.8M | — | — | — | $71.0M | — | — |
| Other non-current assets | $5.5M | $5.6M | $5.5M | $5.5M | $5.4M | $1.4M | $1.5M | $5.3M |
| Accounts payable | $4.4M | $5.2M | $6.2M | $5.5M | $5.3M | $7.2M | $5.4M | $4.4M |
| Accrued liabilities | $43.2M | $41.3M | $51.9M | $31.5M | $27.3M | $29.2M | $32.3M | $26.5M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | $49.9M | $49.7M | $51.9M | $51.8M | $51.6M | $51.3M | $51.1M | $102.5M |
| Other non-current liabilities | $2.7M | $3.7M | $5.5M | $6.0M | $6.4M | $7.9M | $8.9M | $3.1M |
| Common stock & paid-in capital | $3.7M | $3.7M | $3.7M | $3.2M | $3.2M | $2.9M | $2.9M | $2.9M |
| Retained earnings | -$1.38B | -$1.33B | -$1.29B | -$1.21B | -$1.17B | -$1.13B | -$1.06B | -$1.01B |
| Accumulated other comprehensive income (loss) | -$59.9M | -$58.2M | -$58.7M | -$58.9M | -$53.8M | -$52.8M | -$56.7M | -$56.3M |
Cash flow
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.2M | -$77.6M | -$16.4M | -$39.9M | -$44.1M | -$52.8M | -$36.6M | -$32.7M |
| Investing cash flow | $98.6M | -$441.4M | $26.6M | $73.1M | $20.1M | -$26.6M | $47.7M | $77.9M |
| Financing cash flow | $550.0K | $2.4M | $332.2M | $44.0K | $80.7M | -$6.5M | -$53.0M | $50.0K |
| Free cash flow | -$38.4M | -$77.7M | -$16.3M | -$40.2M | -$44.2M | -$52.9M | -$37.0M | -$33.3M |
| Capital expenditures | $140.0K | $119.0K | -$66.0K | $260.0K | $126.0K | $40.0K | $380.0K | $604.0K |
| Share-based compensation | $5.1M | $4.7M | $3.5M | $5.1M | $4.4M | $4.7M | $3.4M | $6.9M |
| Deferred income taxes | $500.0K | $1.1M | $1.1M | — | $500.0K | $2.3M | -$120.0K | — |
| Change in inventory | — | — | — | — | — | -$6.3M | $1.3M | $4.8M |
| Change in accounts payable | -$557.0K | -$1.0M | $649.0K | -$204.0K | -$2.1M | $2.0M | $1.1M | -$918.0K |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | $0 | $53.0M | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | -$185.3M | -$184.3M | -$282.9M | -$143.2M | $310.6M |
| Net income | -$199.0M | -$239.6M | -$308.5M | — | — |
| EPS (diluted) | $-3.46 | $-4.92 | $-6.47 | $-2.71 | $7.04 |
| EPS (basic) | $-3.46 | $-4.92 | $-6.47 | $-2.71 | $7.17 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $824.9M | $556.5M | $831.7M | $705.0M | $809.2M |
| Total liabilities | $626.0M | $563.3M | $624.0M | $229.0M | $213.4M |
| Stockholders' equity | $198.9M | -$6.8M | $207.7M | $476.0M | $595.8M |
| Total current assets | $656.0M | $390.3M | $651.9M | $476.8M | $628.2M |
| Total current liabilities | $62.9M | $40.1M | $73.7M | $75.9M | $36.8M |
| Cash & equivalents | $80.2M | $158.9M | $241.4M | $228.0M | $556.3M |
| Accounts receivable | — | — | — | — | — |
| Inventory | — | — | $12.0M | $6.9M | — |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $13.8M | $20.4M | $46.5M | $50.5M | $43.5M |
| Goodwill | $25.4M | $22.4M | $26.4M | $25.6M | $27.6M |
| Intangible assets | $72.8M | $71.0M | $60.5M | $58.8M | $62.7M |
| Other non-current assets | $5.6M | $1.4M | $3.2M | $6.1M | $5.9M |
| Accounts payable | $5.2M | $7.2M | $6.6M | $11.0M | $2.5M |
| Accrued liabilities | $41.3M | $29.2M | $30.5M | $30.6M | $28.5M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Other current liabilities | — | — | — | $2.2M | $2.9M |
| Long-term debt | $49.7M | $51.3M | $101.7M | $102.8M | $101.0M |
| Other non-current liabilities | $3.7M | $7.9M | $3.7M | $935.0K | $4.2M |
| Common stock & paid-in capital | $3.7M | $2.9M | $2.9M | $2.8M | $2.8M |
| Retained earnings | -$1.33B | -$1.13B | -$890.4M | -$581.9M | -$455.1M |
| Accumulated other comprehensive income (loss) | -$58.2M | -$52.8M | -$53.6M | -$58.3M | -$28.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$178.0M | -$182.7M | -$145.9M | -$145.1M | $288.0M |
| Investing cash flow | -$321.6M | $163.0M | -$205.7M | -$182.7M | -$67.4M |
| Financing cash flow | $415.4M | -$59.5M | $362.7M | $1.4M | $94.9M |
| Free cash flow | -$178.4M | -$186.1M | -$153.1M | -$162.7M | $270.5M |
| Capital expenditures | $439.0K | $3.4M | $7.2M | $17.7M | $17.4M |
| Share-based compensation | $17.7M | $22.3M | $35.1M | $34.2M | $25.6M |
| Deferred income taxes | $1.6M | $2.3M | $1.8M | -$1.5M | $3.2M |
| Change in inventory | — | -$2.4M | $6.7M | $6.9M | — |
| Change in accounts payable | -$2.7M | $1.5M | -$4.2M | $9.2M | -$727.0K |
| Debt issued | — | — | — | — | $64.1M |
| Debt repaid | — | $53.0M | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding QURE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers73.8%
Shares Outstanding66,243,879
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 6,727,777 | $309.9M | 10.16% | +12.9% | 2026-08-14 |
| Jpmorgan Chase & Co | 4,867,755 | $230.8M | 7.35% | +71.6% | 2026-08-12 |
| RTW INVESTMENTS, LP | 3,941,572 | $181.5M | 5.95% | +52.4% | 2026-08-14 |
| State Street Corp | 2,903,825 | $133.8M | 4.38% | +28.5% | 2026-08-07 |
| Aberdeen Group plc | 2,848,117 | $131.2M | 4.30% | -46.3% | 2026-07-31 |
| BlackRock, Inc. | 1,877,453 | $86.5M | 2.83% | +8.3% | 2026-08-07 |
| ORBIMED ADVISORS LLC | 1,807,486 | $83.3M | 2.73% | -15.4% | 2026-08-14 |
| JANE STREET GROUP, LLC | 1,610,483 | $74.2M | 2.43% | +153.2% | 2026-08-14 |
| JENNISON ASSOCIATES LLC | 1,561,412 | $71.9M | 2.36% | +26.6% | 2026-08-03 |
| Boxer Capital Management, LLC | 1,503,300 | $69.2M | 2.27% | +127.1% | 2026-08-14 |
| Goldman Sachs Group Inc | 1,475,956 | $68.0M | 2.23% | +16.8% | 2026-08-14 |
| TWO SIGMA INVESTMENTS, LP | 1,462,024 | $67.3M | 2.21% | -45.4% | 2026-08-07 |
| Two Seas Capital LP | 1,441,410 | $66.4M | 2.18% | +10.9% | 2026-08-12 |
| FMR LLC | 1,270,068 | $58.5M | 1.92% | -27.2% | 2026-08-13 |
| MAK CAPITAL ONE LLC | 1,232,051 | $56.7M | 1.86% | +179.2% | 2026-08-14 |
| MPM BioImpact LLC | 1,225,855 | $56.5M | 1.85% | -10.5% | 2026-08-14 |
| Morgan Stanley | 1,066,639 | $49.1M | 1.61% | +191.3% | 2026-08-11 |
| Vestal Point Capital, LP | 935,000 | $43.1M | 1.41% | +160.4% | 2026-08-14 |
| MAVERICK CAPITAL LTD | 925,383 | $42.6M | 1.40% | +32.6% | 2026-08-14 |
| CITADEL ADVISORS LLC | 910,338 | $41.9M | 1.37% | +125.0% | 2026-08-14 |
| Fiera Capital Corp | 909,141 | $41.9M | 1.37% | +11.3% | 2026-08-07 |
| Integral Health Asset Management, LLC | 900,000 | $41.5M | 1.36% | +0.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 860,631 | $39.7M | 1.30% | +7.0% | 2026-08-12 |
| Longaeva Partners L.P. | 804,594 | $37.1M | 1.21% | +0.0% | 2026-08-13 |
| VANGUARD CAPITAL MANAGEMENT LLC | 779,779 | $35.9M | 1.18% | +12.2% | 2026-06-30 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-04 to 2026-07-02
Recent transactions
- Insiders have net sold 433,229 shares over the last 182 days, across 0 purchases and 38 sales.
- Most recent: Kapusta Matthew C (CEO, Managing Director) — Option exercise of 21,082 shares on 2026-07-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)433,229 sh(38 txns)
Net Shares-433,229
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director | Option exercise | 2026-07-02 | 21,082 |
| Abi-Saab Walid | Chief Medical Officer | Option exercise | 2026-06-30 | 10,000 |
| Kaye Jack | Director | Option exercise | 2026-06-30 | 4,107 |
| Balachandran Madhavan | Director | Option exercise | 2026-06-17 | 5,295 |
| Potts Jeannette | Chief Legal Officer | Open market sale | 2026-06-15 | 5,237 |
| Meek David D. | Director | Open market sale | 2026-06-11 | 1,993 |
| Gut Robert | Director | Open market sale | 2026-06-11 | 2,726 |
| O'Keefe Kylie | Chief Customer & Strat Officer | Open market sale | 2026-06-11 | 15,936 |
| Springhorn Jeremy P. | Director | Open market sale | 2026-06-11 | 1,993 |
| POST LEONARD E | Director | Open market sale | 2026-06-11 | 1,993 |
| Jacques Rachelle Suzanne | Director | Open market sale | 2026-06-11 | 1,993 |
| KLEMT CHRISTIAN | Chief Financial Officer | Grant / award | 2026-03-04 | 39,600 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 21,082 | $19.39 |
| 2026-07-02 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 9,200 | $44.43 |
| 2026-07-02 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 4,282 | $45.43 |
| 2026-07-02 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 7,600 | $45.89 |
| 2026-06-30 | Abi-Saab Walid | Chief Medical Officer | Option exercise | 10,000 | $5.59 |
| 2026-06-30 | Abi-Saab Walid | Chief Medical Officer | Open market sale | 10,000 | $46.46 |
| 2026-06-30 | Abi-Saab Walid | Chief Medical Officer | Open market sale | 20,000 | $46.40 |
| 2026-06-30 | Kaye Jack | Director | Option exercise | 4,107 | $37.00 |
| 2026-06-30 | Kaye Jack | Director | Open market sale | 4,107 | $46.49 |
| 2026-06-30 | Kaye Jack | Director | Option exercise | 17,060 | $20.18 |
| 2026-06-30 | Kaye Jack | Director | Open market sale | 17,060 | $46.43 |
| 2026-06-26 | Abi-Saab Walid | Chief Medical Officer | Open market sale | 1,434 | $46.86 |
| 2026-06-25 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 28,716 | $31.71 |
| 2026-06-25 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 28,716 | $50.02 |
| 2026-06-24 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 4,128 | $31.71 |
| 2026-06-24 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 6,696 | $50.00 |
| 2026-06-18 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 4,656 | $31.71 |
| 2026-06-18 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 4,656 | $50.00 |
| 2026-06-18 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 37,015 | $50.00 |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 62,581 | $19.39 |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 23,977 | $42.61 |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 6,023 | $43.70 |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 32,581 | $45.02 |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 56,929 | $43.43 |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 33,334 | $45.01 |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Open market sale | 11,585 | $48.65 |
| 2026-06-17 | Balachandran Madhavan | Director | Option exercise | 5,295 | $31.71 |
| 2026-06-17 | Balachandran Madhavan | Director | Option exercise | 6,390 | $19.39 |
| 2026-06-17 | Balachandran Madhavan | Director | Open market sale | 5,295 | $47.08 |
| 2026-06-17 | Balachandran Madhavan | Director | Open market sale | 4,700 | $43.66 |
| 2026-06-17 | Balachandran Madhavan | Director | Open market sale | 1,690 | $42.60 |
| 2026-06-17 | Kaye Jack | Director | Option exercise | 5,295 | $31.71 |
| 2026-06-17 | Kaye Jack | Director | Open market sale | 5,295 | $42.57 |
| 2026-06-15 | Balachandran Madhavan | Director | Option exercise | 10,000 | $8.49 |
| 2026-06-15 | Balachandran Madhavan | Director | Open market sale | 10,000 | $27.85 |
| 2026-06-15 | Potts Jeannette | Chief Legal Officer | Open market sale | 5,237 | $27.67 |
| 2026-06-11 | Meek David D. | Director | Open market sale | 1,993 | $27.06 |
| 2026-06-11 | Gut Robert | Director | Open market sale | 2,726 | $27.06 |
| 2026-06-11 | O'Keefe Kylie | Chief Customer & Strat Officer | Open market sale | 15,936 | $27.06 |
| 2026-06-11 | Springhorn Jeremy P. | Director | Open market sale | 1,993 | $27.06 |
| 2026-06-11 | POST LEONARD E | Director | Open market sale | 1,993 | $27.06 |
| 2026-06-11 | Kaye Jack | Director | Open market sale | 1,993 | $27.06 |
| 2026-06-11 | Jacques Rachelle Suzanne | Director | Open market sale | 1,993 | $27.06 |
| 2026-06-11 | Balachandran Madhavan | Director | Open market sale | 1,993 | $27.06 |
| 2026-06-10 | Meek David D. | Director | Grant / award | 7,550 | $0.00 |
| 2026-06-10 | Gut Robert | Director | Option exercise | 2,645 | $16.04 |
| 2026-06-10 | Gut Robert | Director | Open market sale | 2,645 | $26.07 |
| 2026-06-10 | Gut Robert | Director | Open market sale | 3,127 | $26.03 |
| 2026-06-10 | Gut Robert | Director | Open market sale | 1,780 | $26.05 |
| 2026-06-10 | Gut Robert | Director | Grant / award | 7,550 | $0.00 |
| 2026-06-10 | Springhorn Jeremy P. | Director | Grant / award | 7,550 | $0.00 |
| 2026-06-10 | POST LEONARD E | Director | Grant / award | 7,550 | $0.00 |
| 2026-06-10 | Kaye Jack | Director | Grant / award | 7,550 | $0.00 |
| 2026-06-10 | Jacques Rachelle Suzanne | Director | Grant / award | 7,550 | $0.00 |
| 2026-06-10 | Balachandran Madhavan | Director | Grant / award | 7,550 | $0.00 |
| 2026-06-03 | Kaye Jack | Director | Option exercise | 2,645 | $16.04 |
| 2026-06-03 | Kaye Jack | Director | Open market sale | 2,645 | $30.01 |
| 2026-05-08 | Abi-Saab Walid | Chief Medical Officer | Option exercise | 25,000 | $5.59 |
| 2026-05-08 | Abi-Saab Walid | Chief Medical Officer | Open market sale | 25,000 | $25.10 |
| 2026-05-08 | Abi-Saab Walid | Chief Medical Officer | Open market sale | 20,000 | $25.00 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:50 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-02 | 8-K | 2026-09-02 | View on SEC.gov → |
| 2026-07-29 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-02 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-30 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-23 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
Recent news
Headlines about QURE (uniQure N.V. Ordinary Shares). Links open the publisher — we don’t host full articles.
-
QURE Nov 2026 23.000 put (QURE261120P00023000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
QURE Nov 2026 23.000 put (QURE261120P00023000) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-10-21 -
uniQure N.V. Ordinary Shares (QURE) Company Profile
Pluang · 2026-10-21 -
QURE Nov 2026 15.000 call (QURE261120C00015000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-20 -
Will Disappointing Trial Data Change uniQure (QURE) Stock Narrative
Simply Wall Street · 2026-10-20 -
UBS raises target for uniQure stock from USD 27 to USD 48 - ad-hoc-news.de
ad-hoc-news.de · 2026-10-20 -
QURE Nov 2026 42.000 call (QURE261120C00042000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19 -
QURE Nov 2026 26.000 put (QURE261120P00026000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-18
No headlines in this category right now — try “All”.